髄膜炎菌ワクチン：世界の薬剤市場予測・分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 19
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 21
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and Pathophysiology 22
3.1.1 Etiology 22
3.1.2 Pathophysiology 24
3.2 Symptoms 25
3.3 Prognosis 26
4 Epidemiology 27
4.1 Disease Background 27
4.2 Risk Factors and Comorbidities 28
4.2.1 Infants and Young Children are at Greatest Risk for Developing Meningococcal Disease 28
4.2.2 Direct Contact and Overcrowding are the Primary Risk Factors for Infection 29
4.2.3 Exposure is Highest for Those Traveling to the African “Meningitis Belt” 30
4.3 Global Trends 31
4.3.1 US 31
4.3.2 5EU 32
4.3.3 Australia 33
4.3.4 Brazil 33
4.4 Forecast Methodology 34
4.4.1 Sources Used 36
4.4.2 Forecast Assumptions and Methods 39
4.4.3 Sources Not Used 44
4.5 Epidemiology Forecast of Meningococcal Disease (2012-2022) 44
4.5.1 Incident Cases of Meningococcal Disease 44
4.5.2 Age-Specific Incident Cases of Meningococcal Disease 46
4.5.3 Incident Cases of Meningococcal Disease by Serogroup 48
4.6 Discussion 50
4.6.1 Conclusions on Epidemiological Trends 50
4.6.2 Limitations of the Analysis 52
4.6.3 Strengths of the Analysis 52
5 Disease Management 53
5.1 Meningococcal Immunization Policy 54
5.2 US 56
5.2.1 Meningococcal Immunization Recommendations and Policies 56
5.2.2 Clinical Practice 59
5.3 France 61
5.3.1 Meningococcal Immunization Recommendations and Policies 61
5.3.2 Clinical Practice 64
5.4 Germany 65
5.4.1 Meningococcal Immunization Recommendations and Policies 65
5.4.2 Clinical Practice 66
5.5 Italy 67
5.5.1 Meningococcal Immunization Recommendations and Policies 67
5.5.2 Clinical Practice 68
5.6 Spain 69
5.6.1 Meningococcal Immunization Recommendations and Policies 69
5.6.2 Clinical Practice 70
5.7 UK 72
5.7.1 Meningococcal Immunization Recommendations and Policies 72
5.7.2 Clinical Practice 74
5.8 Japan 75
5.8.1 Meningococcal Immunization Recommendations and Policies 75
5.8.2 Clinical Practice 76
5.9 Australia 76
5.9.1 Meningococcal Immunization Recommendations and Policies 76
5.9.2 Clinical Practice 78
5.10 Brazil 80
5.10.1 Meningococcal Immunization Recommendations and Policies 80
5.10.2 Clinical Practice 81
6 Competitive Assessment 83
6.1 Overview 83
6.2 Strategic Competitor Assessment 83
6.3 Product Profiles – Serogroup A,C,W,Y vaccines 85
6.3.1 Menactra 85
6.3.2 Menveo 89
6.3.3 Nimenrix 94
6.3.4 Menomune 98
6.4 Product Profiles – Serogroup B Vaccines 102
6.4.1 Bexsero 102
6.4.2 Trumenba 107
6.5 Product Profiles – Serogroup C Vaccines 112
6.5.1 Meningitec 112
6.5.2 Menjugate 115
6.5.3 NeisVac-C 118
6.5.4 Menitorix 121
6.5.5 MenHibrix 125
7 Opportunity and Unmet Need 130
7.1 Overview 130
7.2 Unmet Needs 131
7.2.1 Unmet Need: Protection Against Serogroup B Disease 131
7.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine 132
7.2.3 Unmet Need: More Cost-Effective Vaccines 133
7.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents 134
7.2.5 Unmet Need: Immunogenic Infant Vaccines 135
7.2.6 Unmet Need: Improved Vaccination Coverage Rates 136
7.2.7 Unmet Need: Increased Patient Awareness and Education 137
7.3 Unmet Needs Gap Analysis 138
7.4 Opportunities 138
7.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations 138
7.4.2 Opportunity: Improving Immune Response Duration with Adjuvants 139
7.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets 140
7.4.4 Opportunity: Reducing the Overall Vaccination Burden by Combining Meningococcal Vaccine with Other Routine Vaccinations 140
8 Pipeline Assessment 141
8.1 Overview 141
8.2 Clinical Trials Mapping 142
8.2.1 Clinical Trials by Country 142
8.2.2 Clinical Trials by Phase and Trial Status 144
8.3 Promising Vaccines in Clinical Development 145
8.3.1 Meninge ACYW conj. 148
8.3.2 MenABCWY 151
8.3.3 MenC Conjugate 154
8.3.4 Heptavalent DTP-Hib-HepB-IPV-MenC 157
9 Current and Future Players 160
9.1 Overview 160
9.2 Trends in Corporate Strategy 165
9.3 Company Profiles 167
9.3.1 Sanofi 167
9.3.2 Pfizer 170
9.3.3 GlaxoSmithKline 172
9.4 Former Players 175
9.4.1 Novartis 175
9.4.2 Baxter 177
9.4.3 Nuron Biotech 177
10 Market Outlook 179
10.1 Global Markets 179
10.1.1 Forecast 179
10.1.2 Drivers and Barriers – Global Issues 183
10.2 United States 186
10.2.1 Forecast 186
10.2.2 Key Events 191
10.2.3 Drivers and Barriers 192
10.3 France 195
10.3.1 Forecast 195
10.3.2 Key Events 199
10.3.3 Drivers and Barriers 200
10.4 Germany 201
10.4.1 Forecast 201
10.4.2 Key Events 205
10.4.3 Drivers and Barriers 206
10.5 Italy 207
10.5.1 Forecast 207
10.5.2 Key Events 211
10.5.3 Drivers and Barriers 212
10.6 Spain 213
10.6.1 Forecast 213
10.6.2 Key Events 217
10.6.3 Drivers and Barriers 218
10.7 United Kingdom 219
10.7.1 Forecast 219
10.7.2 Key Events 223
10.7.3 Drivers and Barriers 224
10.8 Japan 225
10.8.1 Drivers and Barriers 225
10.9 Australia 226
10.9.1 Forecast 226
10.9.2 Key Events 230
10.9.3 Drivers and Barriers 231
10.10 Brazil 232
10.10.1 Forecast 232
10.10.2 Key Events 236
10.10.3 Drivers and Barriers 237
11 Appendix 238
11.1 Bibliography 238
11.2 Abbreviations 264
11.3 Methodology 267
11.4 Forecasting Methodology 267
11.4.1 Vaccine Coverage 268
11.4.2 Vaccine Approval vs. Routine Schedule Inclusion 268
11.4.3 Vaccines Included 269
11.4.4 Key Launch Dates 270
11.4.5 General Pricing Assumptions 271
11.4.6 Individual Vaccine Assumptions 272
11.4.7 Pricing of Pipeline agents 280
11.5 Physicians and Specialists Included in This Study 281
11.6 About the Authors 285
11.6.1 Authors 285
11.6.2 Reviewers 286
11.6.3 Epidemiologists 286
11.6.4 Therapy Area Director 287
11.6.5 Global Director of Therapy Analysis and Epidemiology 287
11.6.6 Global Head of Healthcare 288
11.7 About GlobalData 289
11.8 Disclaimer 289